The effect of botulinum toxin in the masticatory and constrictor musculature of the pharynx as an option in the treatment of obstructive sleep apnea: a case report.

Autor:	Ottoline ACX; Antonio Pedro University Hospital, Fluminense Federal University, Rio de Janeiro, Brazil.; Graduate Program of Neurology, Rio de Janeiro State Federal University (UNIRIO), Rio de Janeiro, Brazil., Viana ADC; Graduate Program of Neurology, Rio de Janeiro State Federal University (UNIRIO), Rio de Janeiro, Brazil.; Department of Otorhinolaryngology, Marcílio Dias Naval Hospital, Rio de Janeiro, Brazil., Migueis DP; Antonio Pedro University Hospital, Fluminense Federal University, Rio de Janeiro, Brazil.; Graduate Program of Neurology, Rio de Janeiro State Federal University (UNIRIO), Rio de Janeiro, Brazil.
Jazyk:	angličtina
Zdroj:	Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine [J Clin Sleep Med] 2024 Oct 17. Date of Electronic Publication: 2024 Oct 17.
DOI:	10.5664/jcsm.11400
Abstrakt:	The botulinum toxin (BT) is US Food and Drug Administration-approved for therapeutic applications in different medical conditions. However, BT is not considered an obstructive sleep apnea (OSA) therapy. OSA is characterized by recurrent airway collapse during sleep, leading to intermittent hypoxia, hypercapnia, and arousal. The application of BT in pharyngeal and masticatory musculature can reduce its constrictive activity, attenuating the obstructions. We present the first case report of a 38-year-old man with severe OSA syndrome who underwent a BT infiltration in palatoglossal, stylohyoid, and masseter muscles bilaterally to treat OSA itself. He had significant clinical and polysomnographic improvement during the muscle afferent block by intramuscular injection of BT, without adverse effects. (© 2024 American Academy of Sleep Medicine.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu